(12) **Translation of European patent specification**

(11) **NO/EP 3230316 B1**

(19) NO

NORWAY

(51) Int Cl.

C07K 16/22 (2006.01) ***A61K 38/17 (2006.01)***
A61K 9/00 (2006.01) ***A61K 39/395 (2006.01)***
A61K 31/00 (2006.01) ***A61K 41/00 (2020.01)***
A61K 31/409 (2006.01) ***A61P 27/02 (2006.01)***
A61K 31/7105 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2022.03.28
(80)	Date of The European Patent Office Publication of the Granted Patent	2022.01.05
(86)	European Application Nr.	15819965.3
(86)	European Filing Date	2015.12.10
(87)	The European Application's Publication Date	2017.10.18
(30)	Priority	2014.12.11, WO, PCT/CN14/093548 2015.09.09, WO, PCT/CN15/089251
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	Bayer HealthCare LLC, 100 Bayer Boulevard PO Box 915, Whippany, NJ 07981, USA
(72)	Inventor	ZEITZ, Oliver, Löwestrasse 20, 10249 Berlin, Tyskland SOWADE, Olaf, Frettchenweg 54, 12623 Berlin, Tyskland WU, Haiyan, Xinlongcheng 33-10-902 Huilongguan Changping, Beijing 100096, Kina
(74)	Agent or Attorney	RWS, Europa House, Chiltern Park, Chiltern Hill, SL99FG CHALFONT ST PETER, Storbritannia

(54) Title **TREATMENT OF AGE RELATED MACULAR DEGENERATION WITH A SMALL ACTIVE CHOROIDAL NEOVASCULARIZATION LESION**

(56) References Cited:

WO-A2-02/062386

ALTAWEEL MICHAEL M ET AL: "Outcomes of Eyes with Lesions Composed of > 50% Blood in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT)", OPHTHALMOLOGY, vol. 122, no. 2, February 2015 (2015-02), pages 391-398, ISSN: 0161-6420(print)

BROWN D M ET AL: "Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study", OPHTHALMOLOGY, J. B. LIPPINCOTT CO., PHILADELPHIA, PA, US, vol. 116, no. 1, 1 January 2009 (2009-01-01), pages 57-65.e5, XP026623775, ISSN: 0161-6420, DOI: 10.1016/J.OPHTHA.2008.10.018 [retrieved on 2009-01-01]

THE PIER STUDY GROUP REGILLO ET AL: "Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-related Macular Degeneration: PIER Study Year 1", AMERICAN JOURNAL OF OPHTHALMOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 145, no. 2, 25 January 2008 (2008-01-25), pages 239-248.e5, XP022433903, ISSN: 0002-9394, DOI: 10.1016/J.AJO.2007.10.004

DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; June 2013 (2013-06), ALTAWEEL MICHAEL ET AL: "Clinical Outcomes of Eyes with Neovascular Lesions Composed of > 50% Blood Treated with Anti-VEGF Therapy in the Comparison of AMD Treatments Trials (CATT)", Database accession no. PREV201800956959 & IOVS, vol. 54, no. 15, June 2013 (2013-06), page 4162, ANNUAL MEETING OF THE ASSOCIATION-FOR-RESEARCH-IN-VISION-AND-OPH THALMOLOGY (ARVO); SEATTLE, WA, USA; MAY 05 -09, 2013 ISSN: 0146-0404(print)
JEFFREY S. HEIER ET AL: "Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration", OPHTHALMOLOGY, vol. 119, no. 12, 1 December 2012 (2012-12-01), pages 2537-2548, XP55138976, ISSN: 0161-6420, DOI: 10.1016/j.ophtha.2012.09.006
OHR MATTHEW ET AL: "Aflibercept in wet age-related macular degeneration: a perspective review.", THERAPEUTIC ADVANCES IN CHRONIC DISEASE JUL 2012, vol. 3, no. 4, July 2012 (2012-07), pages 153-161, ISSN: 2040-6223
GUI-SHUANG YING ET AL: "Baseline Predictors for One-Year Visual Outcomes with Ranibizumab or Bevacizumab for Neovascular Age-related Macular Degeneration", OPHTHALMOLOGY., vol. 120, no. 1, 1 January 2013 (2013-01-01), pages 122-129, XP55252719, US ISSN: 0161-6420, DOI: 10.1016/j.ophtha.2012.07.042
Robert P. Finger ET AL: "Predictors of anti-VEGF treatment response in neovascular age-related macular degeneration", SURVEY OF OPHTHALMOLOGY., vol. 59, no. 1, 1 January 2014 (2014-01-01), pages 1-18, XP55495272, XX ISSN: 0039-6257, DOI: 10.1016/j.survophthal.2013.03.009
ROSENFELD PHILIP J ET AL: "Ranibizumab for neovascular age-related macular degeneration", NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, US, vol. 355, no. 14, 5 October 2006 (2006-10-05), pages 1419-1431, XP002506588, ISSN: 0028-4793, DOI: 10.1056/NEJMOA054481
DAVID M. BROWN ET AL: "Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration", NEW ENGLAND JOURNAL OF MEDICINE, vol. 355, no. 14, 5 October 2006 (2006-10-05), pages 1432-1444, XP055252324, US ISSN: 0028-4793, DOI: 10.1056/NEJMoa062655
JAVIER ZARRANZ-VENTURA ET AL: "The Neovascular Age-Related Macular Degeneration Database", OPHTHALMOLOGY., vol. 121, no. 10, 1 October 2014 (2014-10-01), pages 1966-1975, XP55252725, US ISSN: 0161-6420, DOI: 10.1016/j.ophtha.2014.04.026
BEAUMONT PAUL E ET AL: "Lesion morphology in age-related macular degeneration and its therapeutic significance", ARCHIVES OF OPHTHALMOLOGY, vol. 124, no. 6, June 2006 (2006-06), pages 807-812, ISSN: 0003-9950

Patentkrav

1. VEGF-antagonist til bruk i behandling av våt aldersrelatert makuladegenerasjon (wAMD) hos en pasient, der det først blir brakt på det rene om størrelsen av den aktive CNV-lesjonen er mindre enn 50 % av den totale lesjonsstørrelsen, slik det blir bestemt ved fluorescein-angiografi, og deretter blir pasienten behandlet med en anti-VEGF-behandling dersom størrelsen av den aktive CNV-lesjonen er mindre enn 50 % av den totale lesjonsstørrelsen, der VEGF-antagonisten er aflibercept.

2. VEGF-antagonist til bruk i behandling av wAMD ifølge krav 1, der den initielle anti-VEGF-behandlingen omfatter minst 3 injeksjoner av VEGF-antagonisten med fire ukers mellomrom hver.